PubMed Health⌕ Search

Biomedical subjects

M Elizabeth Halloran

Publications and source records attributed to M Elizabeth Halloran.

At least 19 recordsLinked to original sources

Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials.

Four household-based, randomized clinical trials, two each of zanamivir and oseltamivir, were designed primarily to estimate the effect of postexposure prophylaxis on preventing influenza illness in household contacts. However, the effect of influenza antivirals on infectiousness as well as on the ability of the virus to cause disease--the pathogenicity--have important public health consequences. The authors show how such studies can provide estimates of pathogenicity, antiviral efficacy for pathogenicity, and the antiviral effect on infectiousness. Analysis of the four studies confirmed the high prophylactic efficacy against illness of both zanamivir (75%, 95% confidence interval (CI): 54, 86) and oseltamivir (81%, 95% CI: 35, 94). The effect on reducing infectiousness was 19% (95% CI: -160, 75) for zanamivir and 80% (95% CI: 43, 93) for oseltamivir. Pathogenicity in controls ranged from 44% (95% CI: 33, 55) to 66% (95% CI: 48, 72). Efficacy in reducing pathogenicity for zanamivir was 52% (95% CI: 19, 72) and 56% (95% CI: 14, 77) in the two studies; for oseltamivir, it was 56% (95% CI: 10, 73) and 79% (95% CI: 45, 92). Studies of influenza antivirals in transmission units would be improved if randomization schemes were used that allow estimation of the antiviral effect on infectiousness from individual studies.

Antiviral Agents↗

Containing a large bioterrorist smallpox attack: a computer simulation approach.

BACKGROUND: A bioterrorist release of smallpox is a constant threat to the population of the USA and other countries. DESIGN: A stochastic simulation model of the spread of smallpox due to a large bioterrorist attack in a structured population was constructed. Disease natural history parameter estimates, time lines of behavioral activities, and control scenarios were based on the literature and on the consensus opinion of a panel of smallpox experts. RESULTS: The authors found that surveillance and containment, i.e., isolation of known cases and vaccination of their close contacts, would be sufficient to effectively contain a large intentional smallpox release. Given that surveillance and containment measures are in place, preemptive vaccination of hospital workers would further reduce the number of smallpox cases and deaths but would require large numbers of prevaccinations. High levels of reactive mass vaccination after the outbreak begins would further reduce smallpox cases and deaths to a minimum, but would require even larger numbers of vaccinations. Reactive closure of schools would have a minimal effect. CONCLUSION: A rapid and well-organized response to a bioterrorist attack would be necessary for effective surveillance and containment to control spread. Preemptive vaccination of hospital workers and reactive vaccination of the target population would further limit spread, but at a cost of many more vaccinated. This cost in resources and potential harm due to vaccination will have to be weighed against the potential benefits should an attack occur. Prevaccination of the general population is not necessary.

Bioterrorism↗

On estimation of vaccine efficacy using validation samples with selection bias.

Using validation sets for outcomes can greatly improve the estimation of vaccine efficacy (VE) in the field (Halloran and Longini, 2001; Halloran and others, 2003). Most statistical methods for using validation sets rely on the assumption that outcomes on those with no cultures are missing at random (MAR). However, often the validation sets will not be chosen at random. For example, confirmational cultures are often done on people with influenza-like illness as part of routine influenza surveillance. VE estimates based on such non-MAR validation sets could be biased. Here we propose frequentist and Bayesian approaches for estimating VE in the presence of validation bias. Our work builds on the ideas of Rotnitzky and others (1998, 2001), Scharfstein and others (1999, 2003), and Robins and others (2000). Our methods require expert opinion about the nature of the validation selection bias. In a re-analysis of an influenza vaccine study, we found, using the beliefs of a flu expert, that within any plausible range of selection bias the VE estimate based on the validation sets is much higher than the point estimate using just the non-specific case definition. Our approach is generally applicable to studies with missing binary outcomes with categorical covariates.

Adolescent↗

Containing pandemic influenza at the source.

Highly pathogenic avian influenza A (subtype H5N1) is threatening to cause a human pandemic of potentially devastating proportions. We used a stochastic influenza simulation model for rural Southeast Asia to investigate the effectiveness of targeted antiviral prophylaxis, quarantine, and pre-vaccination in containing an emerging influenza strain at the source. If the basic reproductive number (R0) was below 1.60, our simulations showed that a prepared response with targeted antivirals would have a high probability of containing the disease. In that case, an antiviral agent stockpile on the order of 100,000 to 1 million courses for treatment and prophylaxis would be sufficient. If pre-vaccination occurred, then targeted antiviral prophylaxis could be effective for containing strains with an R0 as high as 2.1. Combinations of targeted antiviral prophylaxis, pre-vaccination, and quarantine could contain strains with an R(0) as high as 2.4.

Adolescent↗

Strategy for distribution of influenza vaccine to high-risk groups and children.

Despite evidence that vaccinating schoolchildren against influenza is effective in limiting community-level transmission, the United States has had a long-standing government strategy of recommending that vaccine be concentrated primarily in high-risk groups and distributed to those people who keep the health system and social infrastructure operating. Because of this year's influenza vaccine shortage, a plan was enacted to distribute the limited vaccine stock to these groups first. This vaccination strategy, based on direct protection of those most at risk, has not been very effective in reducing influenza morbidity and mortality. Although it is too late to make changes this year, the current influenza vaccine crisis affords the opportunity to examine an alternative for future years. The alternative plan, supported by mathematical models and influenza field studies, would be to concentrate vaccine in schoolchildren, the population group most responsible for transmission, while also covering the reachable high-risk groups, who would also receive considerable indirect protection. In conjunction with a plan to ensure an adequate vaccine supply, this alternative influenza vaccination strategy would help control interpandemic influenza and be instrumental in preparing for pandemic influenza. The effectiveness of the alternative plan could be assessed through nationwide community studies.

Adolescent↗

Population-wide benefits of routine vaccination of children against influenza.

Using a stochastic simulation model of influenza transmission, clinical illness, and economic costs, we estimated the population-wide benefits of routinely vaccinating US children (ages 6 months to 18 years) against influenza. Disease burden was projected to decline as a result of both reduced susceptibility to infection among vaccinees and reductions in disease transmission to others in the community. Vaccination of 20% of children would reduce the total number of influenza cases in the US by 46%; 80% coverage would reduce the total number of cases by 91%. Similar reductions were estimated to occur in influenza-related mortality and economic costs.

Adolescent↗

Finding optimal vaccination strategies for pandemic influenza using genetic algorithms.

In the event of pandemic influenza, only limited supplies of vaccine may be available. We use stochastic epidemic simulations, genetic algorithms (GA), and random mutation hill climbing (RMHC) to find optimal vaccine distributions to minimize the number of illnesses or deaths in the population, given limited quantities of vaccine. Due to the non-linearity, complexity and stochasticity of the epidemic process, it is not possible to solve for optimal vaccine distributions mathematically. However, we use GA and RMHC to find near optimal vaccine distributions. We model an influenza pandemic that has age-specific illness attack rates similar to the Asian pandemic in 1957-1958 caused by influenza A(H2N2), as well as a distribution similar to the Hong Kong pandemic in 1968-1969 caused by influenza A(H3N2). We find the optimal vaccine distributions given that the number of doses is limited over the range of 10-90% of the population. While GA and RMHC work well in finding optimal vaccine distributions, GA is significantly more efficient than RMHC. We show that the optimal vaccine distribution found by GA and RMHC is up to 84% more effective than random mass vaccination in the mid range of vaccine availability. GA is generalizable to the optimization of stochastic model parameters for other infectious diseases and population structures.

Adolescent↗

Estimating vaccine efficacy using auxiliary outcome data and a small validation sample.

In vaccine studies, a specific diagnosis of a suspected case by culture or serology of the infectious agent is expensive and difficult. Implementing validation sets in the study is less expensive and is easier to carry out. In studies using validation sets, the non-specific or auxiliary outcome is measured on each participant while the specific outcome is measured only for a small proportion of the participants. Vaccine efficacy, defined as one minus some measure of relative risk, could be severely attenuated if based only on the auxiliary outcome. Applying missing data analysis techniques could thus correct the bias while maintaining statistical efficiency. However, when the sample size in the validation sets is small and the vaccine is highly efficacious, all specific outcomes are likely to be negative in the validation set in the vaccinated group. Two commonly used missing data analysis methods, the mean score method and multiple imputation, depend on the ad hoc continuity correction when none of the specific outcomes are positive and the normality or log-normality assumption of relative risk, which may not hold when the relative risk is highly skewed, to estimate the confidence interval. In this paper, we propose a Bayesian method to estimate vaccine efficacy and its highest probability density (HPD) credible set using Monte Carlo (MC) methods when using auxiliary outcome data and a small validation sample. Comparing the performance of these approaches using data from a field study of influenza vaccine and simulations, we recommend to use the Bayesian method in this situation.

Adolescent↗

Containing pandemic influenza with antiviral agents.

For the first wave of pandemic influenza or a bioterrorist influenza attack, antiviral agents would be one of the few options to contain the epidemic in the United States until adequate supplies of vaccine were available. The authors use stochastic epidemic simulations to investigate the effectiveness of targeted antiviral prophylaxis to contain influenza. In this strategy, close contacts of suspected index influenza cases take antiviral agents prophylactically. The authors compare targeted antiviral prophylaxis with vaccination strategies. They model an influenza pandemic or bioterrorist attack for an agent similar to influenza A virus (H2N2) that caused the Asian influenza pandemic of 1957-1958. In the absence of intervention, the model predicts an influenza illness attack rate of 33% of the population (95% confidence interval (CI): 30, 37) and an influenza death rate of 0.58 deaths/1,000 persons (95% Cl: 0.4, 0.8). With the use of targeted antiviral prophylaxis, if 80% of the exposed persons maintained prophylaxis for up to 8 weeks, the epidemic would be contained, and the model predicts a reduction to an illness attack rate of 2% (95% Cl: 0.2, 16) and a death rate of 0.04 deaths/1,000 persons (95% CI: 0.0003, 0.25). Such antiviral prophylaxis is nearly as effective as vaccinating 80% of the population. Vaccinating 80% of the children aged less than 19 years is almost as effective as vaccinating 80% of the population. Targeted antiviral prophylaxis has potential as an effective measure for containing influenza until adequate quantities of vaccine are available.

Adolescent↗

Estimating heterogeneous transmission with multiple infectives using MCMC methods.

We developed a general procedure for estimating the transmission probability adjusting for covariates when susceptibles are exposed to several infectives concurrently and taking correlation within transmission units into account. The procedure is motivated by a study estimating efficacy of pertussis vaccination based on the secondary attack rate in a rural sub-Saharan community (Niakhar, Senegal) and illustrated with simulations. The procedure is also appropriate to estimate the pairwise transmission probability in transmission studies of live vaccine virus in a collection of transmission units, such as day-care centres or retirement centres. Previously, analyses either excluded transmission units with multiple infectives or ignored co-infectives. Excluding transmission units with multiple infectives is statistically less efficient and ignoring co-infectives can lead to biased estimation. Modelling is carried out by regressing the latent pairwise transmission probability from each infective to a susceptible on covariates and specifying a transmission linkage function linking the latent pairwise transmission probability to the overall transmission probability. Parameters are estimated using Markov chain Monte Carlo methods.

Bayes Theorem↗

Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.

BACKGROUND: The efficacy of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine (CAIV-T) against influenza A(H3N2) and B infections in healthy persons is established, but its effectiveness against natural influenza A(H1N1) infection is unknown. OBJECTIVE: To assess the effectiveness of CAIV-T in healthy children during the 2000-2001 influenza A(H1N1) and B epidemic. DESIGN: Community-based, nonrandomized, open-label trial from August 1998 through April 2001. SETTING: Intervention and comparison communities in central Texas. PARTICIPANTS: Healthy children, aged 1.5 to 18 years, from the intervention communities received a single dose of CAIV-T at least 1 time or more in 1998, 1999, and/or 2000. MAIN OUTCOME MEASURES: The incidence of medically attended acute respiratory illnesses during the 2000-2001 influenza epidemic was compared in 3794 health plan CAIV-T recipients with age-eligible, health plan nonrecipients in the intervention communities for direct effectiveness (n = 9325), and with those in the 2 comparison communities for total effectiveness (n = 16,264). RESULTS: The 2281 CAIV-T recipients in 2000 had significant direct protection against medically attended acute respiratory illness of 18% to 20% during the biphasic influenza A(H1N1) and B epidemic, and 17% to 26% during influenza A(H1N1) predominance. The 931 recipients of CAIV-T in 1999 containing influenza A/Beijing/262/95(H1N1) and B/Beijing/184/93-like viruses had persistent heterovariant protection against the 2000-2001 influenza A/New Caledonia/20/99(H1N1) and B/Sichuan/379/99 variants. The 616 recipients of a single CAIV-T dose in 1999 only, including those younger than 5 years with no prior natural exposure to influenza A(H1N1) viruses, showed persistent protection. CONCLUSION: Healthy children who received CAIV-T in 2000 or 1999 were protected against new variants of influenza A(H1N1) and B in the 2000-2001 influenza epidemic.

Acute Disease↗

Bayesian estimation of vaccine efficacy.

Protective vaccine efficacy, VEs, is measured as one minus the incidence rate ratio (IRR) or the relative risk (RR) in the vaccinated group compared with the unvaccinated group. In this paper, we systematically present Bayesian estimation of protective vaccine efficacy based on the Poisson and binomial distributions. We also propose a new tool, the vaccine efficacy acceptability curve, to represent the uncertainty for the estimate of the vaccine efficacy graphically. It is very useful, especially when there is no universal agreement on the acceptable vaccine efficacy. The vaccine efficacy acceptability curve is defined as the posterior probability that the measure of vaccine efficacy VEs > or = k for each acceptable value k. When a vaccine is highly efficacious, the number of vaccinated susceptibles being infected is likely to be very small or even zero. Then the assumptions of normality and log-normality of IRR or RR usually do not hold well. Although frequentist exact methods provide good estimates of the confidence interval, they are overly conservative and are computationally difficult to extend to estimate the vaccine efficacy acceptability curve. In this paper, our focus is on Bayesian estimation of protective vaccine efficacy, its highest probability density credible set, and the vaccine efficacy acceptability curve through Markov chain Monte Carlo (MCMC) methods. We illustrate the methods using the data from two pertussis vaccine studies and the H. influenza Type B preventive trial.

Bayes Theorem↗

A family study of lymphedema of the leg in a lymphatic filariasis-endemic area.

The risk of filarial lymphedema may not be equivalent for all members of filaria-exposed populations. While evidence for a genetic factor that influences acquisition of infection has been growing, very little work has addressed whether there is a genetic basis to the development of disease due to lymphatic filariasis. We designed a family study of lymphedema in a rural community in Haiti to assess disease aggregation. Three hundred sixty-eight female patients sixteen years of age or older were enrolled at a lymphedema treatment clinic between June 1995 and December 1999. After applying additional eligibility criteria, 172 probands were enrolled into the family study for detailed pedigree collection between September 1998 and December 1999. Fifty-three lymphedema cases were identified among the probands' parents, full-siblings, children, half-siblings, and mating partners of the parents. Twelve of the 53 cases were among males. The proportion of cases occurring in a biologic parent of the proband was higher than in unrelated individuals married into the proband's family (P = 0.0010). This is the first large family study based on pedigrees to assess the familial aggregation of lymphedema due to filariasis. This family study will be useful to investigate the role of genes and environment in the development of filarial-related lymphedema.

Adolescent↗

Assessment of families for excess risk of lymphedema of the leg in a lymphatic filariasis-endemic area.

The influence of host genes on the distribution of lymphedema due to lymphatic filariasis is unknown. To assess this, pedigree and disease information were collected from lymphedema patients in a lymphatic filariasis-endemic area. These patients were female, with an average age of approximately 40 years, who were enrolled between June 1995 and July 1999 in a lymphedema treatment clinic, and from the rural Haitian community served by the clinic. Interviews were conducted between September 1998 and December 1999. Families with multiple lymphedema cases were of similar size, with an average of 15 members, as those families with only a single lymphedema case. We determined whether families observed to have multiple lymphedema cases had a higher prevalence of lymphedema than expected when stratified population estimates and family size were considered. Lymphedema of the leg was excessive in 15 of 43 families with multiple lymphedema cases. The number of families demonstrating excess disease was significantly different than was expected based on population estimates of lymphedema prevalence (P = 0.026). Families with multiple cases of lymphedema were not significantly larger in family size than families with a single lymphedema cases. Twelve of the 15 families had a male with lymphedema, which influenced the interpretation of the results. The significance of these results is discussed.

Adult↗

Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity.

We estimated the effectiveness of pertussis vaccination in reducing the clinical severity of breakthrough disease among vaccinated individuals from a comprehensive follow-up study of a community of 30,000 residents of Niakhar, Senegal, in 1993. A physician examined all children with potential pertussis (cough of >7 days' duration). Samples were collected from 97% of these children for culture or serologic testing as part of the active surveillance for a pertussis vaccine trial. Cases of pertussis were defined by confirmation through culture or serologic testing or by a history of contact with a person with culture-confirmed pertussis. Among children with confirmed cases, severity of illness was assessed according to a scale that combined clinical signs and symptoms. The efficacy of the vaccine in reducing disease severity was 48% (95% confidence interval, 39%-55%) among children vaccinated with 3 doses of whole-cell (67%) or acellular (32%) vaccine. Primary cases were more severe than secondary cases in residential compounds. Pertussis vaccination is effective in reducing the severity of illness.

Bordetella pertussis↗